• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Email
  • Facebook
  • Twitter

International Alliance of ALS/MND Associations

  • Members’ Login
  • Contact
  • Join
  • Donate
  • What is ALS/MND?
  • Events
    • Alliance Meeting 2021
    • Allied Professionals Forum 2021
    • ALS/MND Connect 2021
    • International Symposium on ALS/MND 2021
    • Awards
    • Webinars
  • March of Faces
  • Find an Association
  • Support for Members
    • Partnership Programme
    • Mentorship Programme
    • Alliance Support Grant
  • Advocacy
    • Advocacy Toolkit
    • Rights of People with ALS/MND
    • Biogen – Tofersen
    • BrainStorm Cell Therapeutics – NurOwn
    • Collaborative Medicinal Development – CuATSM
    • Cytokinetics – Reldasemtiv
    • Right to Try
    • Unproven (Off-Label) Treatments
    • US FDA Orphan Drug Designation
    • T Regulatory Cell Therapies
    • Amylyx – AMX0035
    • Kadimastem – AstroRx
  • Global Day
  • Resources
    • Submit a Resource
  • Newsletters
  • About
    • About the Alliance
    • Newsletter subscription
    • Board of Directors
    • Committees/Advisory Councils
      • Scientific Advisory Council
      • PALS and CALS Advisory Council
      • Innovation and Technology Council
      • Governance Committee
      • Budget and Finance Committee
    • Staff
    • History

Click here for Coronavirus (COVID-19) updates

Information brève sur la sclérose latérale amyotrophique (SLA)

La sclérose latérale amyotrophique (SLA) est une maladie dégénérative du système nerveux central à évolution rapide. Les patients perdent de la masse musculaire en permanence. Ce sont les muscles des bras et des jambes, des organes de la voix, de la mastication et de la déglutition. L’évolution de la maladie est très diverse. La plupart des patients survivent de trois à cinq ans avec une paralysie progressive. La cause de cette maladie n’est pas encore élucidée. La plupart des cas surviennent de façon sporadique (SLA sporadique, SLAs), c’est-à-dire sans prédisposition familiale. Une prédisposition familiale (SLA familiale, SLAf) n’est observée que dans un nombre réduit de cas (5 à 10 %).

http://www.sla-suisse.ch/fr/quest-ce_que_la_sla/image_de_la_maladie/

Language: French
Subject areas: What Is ALS/MND?

Primary Sidebar

Back to resources

Allied Professionals Forum Registration

The International Alliance of ALS/MND Associations will host a virtual Allied Professionals Forum spread over two days to accommodate time zones on 3 – 4 December 2020.

Click here to register for the Allied Professionals Forum

Footer

Support the Alliance

Please donate

Please consider making a donation to support our work. Thank you!

Latest Tweets

  • Creativity takes Courage! (Henri Matisse)In celebration of World Art Day (April 15th), tag an artist or share this… https://t.co/yfn4D6gmmA April 14, 2021 12:00 am
  • https://t.co/aKxWOqKnDZ @AsociacionELAar #ALSMNDWithoutBorders April 13, 2021 8:48 pm
  • maybe there is an opportunity for @TaylorMadeGolf to outfit wheelchairs around the world! #ALSMNDWithoutBorders https://t.co/qWFfwdJ3Eg April 13, 2021 3:36 pm

Keep in touch

Sign up to receive updates and to hear what's going on in the International Alliance of ALS/MND Associations.

Return to top of page
  • Disclaimer
  • Privacy notice & Cookies
  • Sitemap

Copyright © 2021 The International Alliance of ALS/MND Associations. All rights reserved.

Registered in England: Charity Number 1079504 · Site built by graphics.coop · Powered by WordPress · Members' login